Clinical Trials in Manchester, UK

Clinical Trials in Manchester

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Not yet open

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

Boehringer Ingelheim

Phase 3

466

Birmingham, Exeter, Leeds, Leicester, London, Manchester, Oxford

2026-09-14

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

Boehringer Ingelheim

Phase 3

390

Cambridge, Edinburgh, Manchester

2026-07-10

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Boehringer Ingelheim

Phase 3

670

Cardiff, Leicester, Manchester, Sutton, Torquay

2026-04-13

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

Boehringer Ingelheim

Phase 3

400

Cardiff, Edinburgh, London, Manchester, Sutton

2026-01-16

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

Boehringer Ingelheim

Phase 2

588

Dundee, London, Manchester

2024-10-11

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

Boehringer Ingelheim

Phase 1/2

768

Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton

2024-06-28

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma

Boehringer Ingelheim

Phase 2

204

Leicester, London, Manchester, Newcastle upon Tyne

2023-10-13

Active, closed

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

NCT04973163Solid Tumors, KRAS Mutation

Boehringer Ingelheim

Phase 1

Manchester

2021-09-09

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/manchester

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →